| Followers | 59 |
| Posts | 7595 |
| Boards Moderated | 0 |
| Alias Born | 10/20/2014 |
Tuesday, July 29, 2025 10:01:23 PM
Honestly, I would hope there is some grand master plan that Alex Denner is focused on.
However, I am disgusted by the botched share buyback plan that never happened. Some
hint from management that they have a strategic plan to develop the one-a-day version of
Vascepa. All of the past managements of Amarin have taken a great drug and laid it to waste.
When Marzac was going after the fraud management would not back him. How more stupid
could management at the time have been. China's approval of Vascep seems to never gain
any traction...The same for the rest of the world. If Denner were to have any confidence in
this company he would increase the stake held by Sarissa and then initiate a share buyback
program. Until management makes some concrete moves to show confidence in this company
the share price will simply languish. Why has management not stepped up to buy shares with
their own money? Until they do I will not get excited about anything AMRN says or does.
However, I am disgusted by the botched share buyback plan that never happened. Some
hint from management that they have a strategic plan to develop the one-a-day version of
Vascepa. All of the past managements of Amarin have taken a great drug and laid it to waste.
When Marzac was going after the fraud management would not back him. How more stupid
could management at the time have been. China's approval of Vascep seems to never gain
any traction...The same for the rest of the world. If Denner were to have any confidence in
this company he would increase the stake held by Sarissa and then initiate a share buyback
program. Until management makes some concrete moves to show confidence in this company
the share price will simply languish. Why has management not stepped up to buy shares with
their own money? Until they do I will not get excited about anything AMRN says or does.
Recent AMRN News
- Amarin Highlights New REDUCE-IT Analysis Showing Risk-Weighted ApoB May Improve Cardiovascular Risk Detection (AMRN) • IH Market News • 05/27/2026 03:24:38 PM
- New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia • GlobeNewswire Inc. • 05/27/2026 12:00:00 PM
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
